BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 7751474)

  • 1. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias.
    Triscott JA; Ritter JH; Swanson PE; Wick MR
    J Cutan Pathol; 1995 Feb; 22(1):2-10. PubMed ID: 7751474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. bcl-2 protein expression and correlation with the interchromosomal 14;18 translocation in cutaneous lymphomas and pseudolymphomas.
    Cerroni L; Volkenandt M; Rieger E; Soyer HP; Kerl H
    J Invest Dermatol; 1994 Feb; 102(2):231-5. PubMed ID: 8106752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value.
    Wang T; Lasota J; Hanau CA; Miettinen M
    APMIS; 1995 Sep; 103(9):655-62. PubMed ID: 7488387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cutaneous b-cell lymphomas of follicular and marginal zone types: use of Bcl-6, CD10, Bcl-2, and CD21 in differential diagnosis and classification.
    de Leval L; Harris NL; Longtine J; Ferry JA; Duncan LM
    Am J Surg Pathol; 2001 Jun; 25(6):732-41. PubMed ID: 11395550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoreactivity for bcl-2 protein in cutaneous lymphomas and lymphoid hyperplasias.
    Cerroni L; Kerl H
    J Cutan Pathol; 1995 Oct; 22(5):476-8. PubMed ID: 8594083
    [No Abstract]   [Full Text] [Related]  

  • 6. Bcl-2, Bcl-6 and CD10 expression in cutaneous B-cell lymphoma: further support for a follicle centre cell origin and differential diagnostic significance.
    Hoefnagel JJ; Vermeer MH; Jansen PM; Fleuren GJ; Meijer CJ; Willemze R
    Br J Dermatol; 2003 Dec; 149(6):1183-91. PubMed ID: 14674895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cutaneous B cell processes with nodular pattern].
    Chirife AM; Bilbao ER; Giménez L; Marino L
    Medicina (B Aires); 2006; 66(4):307-12. PubMed ID: 16977965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of MT2 and anti-bcl-2 protein antibodies in the differentiation of benign from malignant cutaneous infiltrates of B-lymphocytes with germinal center formation.
    Chimenti S; Cerroni L; Zenahlik P; Peris K; Kerl H
    J Cutan Pathol; 1996 Aug; 23(4):319-22. PubMed ID: 8864918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates.
    Dummer R; Michie SA; Kell D; Gould JW; Haeffner AC; Smoller BR; Warnke RA; Wood GS
    J Cutan Pathol; 1995 Feb; 22(1):11-7. PubMed ID: 7751472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
    Baldassano MF; Bailey EM; Ferry JA; Harris NL; Duncan LM
    Am J Surg Pathol; 1999 Jan; 23(1):88-96. PubMed ID: 9888708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of the t(14;18) chromosomal translocation in primary cutaneous B-cell lymphoma.
    Child FJ; Russell-Jones R; Woolford AJ; Calonje E; Photiou A; Orchard G; Whittaker SJ
    Br J Dermatol; 2001 Apr; 144(4):735-44. PubMed ID: 11298531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apoptotic index: discriminant feature for the differentiation of cutaneous diffuse malignant follicular center cell lymphomas from lymphoid hyperplasia.
    Miracco C; Spina D; Santopietro R; Sforza V; Leoncini L; Pacenti L; de Santi MM; Lio R; Luzi P; Tosi P
    J Invest Dermatol; 1993 May; 100(5):699-704. PubMed ID: 8491993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TOX expression in cutaneous B-cell lymphomas.
    Schrader AM; Jansen PM; Willemze R
    Arch Dermatol Res; 2016 Aug; 308(6):423-7. PubMed ID: 27180090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma.
    Cerroni L; Signoretti S; Höfler G; Annessi G; Pütz B; Lackinger E; Metze D; Giannetti A; Kerl H
    Am J Surg Pathol; 1997 Nov; 21(11):1307-15. PubMed ID: 9351568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cutaneous lymphoid hyperplasia. Immunologic characteristics and assessment of criteria recently proposed as diagnostic of malignant lymphoma.
    Medeiros LJ; Picker LJ; Abel EA; Hu CH; Hoppe RT; Warnke RA; Wood GS
    J Am Acad Dermatol; 1989 Nov; 21(5 Pt 1):929-42. PubMed ID: 2808829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staining for Bcl-2 protein helps to distinguish benign from malignant lymphoid aggregates in bone marrow biopsies.
    Ben-Ezra JM; King BE; Harris AC; Todd WM; Kornstein MJ
    Mod Pathol; 1994 Jun; 7(5):560-4. PubMed ID: 7937722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features.
    Mirza I; Macpherson N; Paproski S; Gascoyne RD; Yang B; Finn WG; Hsi ED
    J Clin Oncol; 2002 Feb; 20(3):647-55. PubMed ID: 11821444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma.
    Ritter JH; Dresler CM; Wick MR
    Hum Pathol; 1995 Nov; 26(11):1227-32. PubMed ID: 7590697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bcl-2 gene rearrangements in primary B-cell lymphoma of the gastrointestinal tract reveal follicular lymphoma as a subtype.
    Straka C; Mielke B; Eichelmann A; Trede I; Ho AD; Möller P
    Leukemia; 1993 Feb; 7(2):268-73. PubMed ID: 8426481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas.
    Dogan A; Bagdi E; Munson P; Isaacson PG
    Am J Surg Pathol; 2000 Jun; 24(6):846-52. PubMed ID: 10843287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.